Companies › Suven Life Sciences
2 active drug programs in 2 registered trials: 2 Phase 3; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Masupirdine (SUVN-502) Serotonin 6 (5-HT6) receptor antagonist | HTR6 | Phase 3 | Agitation | Dec 2026 |
| Suvn-G3031 Histamine H3 receptor inverse agonist | HRH3 | Phase 3 | Narcolepsy | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05397639 | Masupirdine (SUVN-502) | Phase 3 | Agitation | Neurology | Dec 2026 |
| NCT07540364 | Suvn-G3031 | Phase 3 | Narcolepsy | Neurology | Nov 2027 |
Bigespas JYAMS PET Research & Development Longboard Pharmaceuticals TriGemX Bio Zogenix
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.